Goodwill - Additional Information (Details) |
12 Months Ended | ||
|---|---|---|---|
|
Aug. 02, 2018
USD ($)
Y
$ / shares
|
Dec. 31, 2025
USD ($)
shares
|
Dec. 31, 2024
USD ($)
|
|
| Goodwill | |||
| Goodwill | $ 260,016 | $ 247,685 | |
| Warrants exercised during the period | shares | 0 | ||
| Impairment of goodwill | $ 0 | ||
| Forfeiture rate | |||
| Goodwill | |||
| Derivative liability, measurement input | 0 | ||
| Stock price | |||
| Goodwill | |||
| Derivative liability, measurement input | $ / shares | 0.067 | ||
| Exercise price | |||
| Goodwill | |||
| Derivative liability, measurement input | $ / shares | 0.1 | ||
| Volatility | |||
| Goodwill | |||
| Derivative liability, measurement input | 3.29 | ||
| Expected life | |||
| Goodwill | |||
| Derivative liability, measurement input | Y | 2 | ||
| Expected dividend rate | |||
| Goodwill | |||
| Derivative liability, measurement input | 0 | ||
| Visava Inc | |||
| Goodwill | |||
| Purchase consideration | $ 3,318,842 | ||
| Visava Inc | Canary Rx Inc | |||
| Goodwill | |||
| Fair value of net liabilities | 275,353 | ||
| Purchase consideration | 3,318,842 | ||
| Goodwill | $ 3,594,195 | ||
| Visava Inc | Risk free interest rate | |||
| Goodwill | |||
| Derivative liability, measurement input | 0.0266 |
| X | ||||||||||
- Definition Represents the information pertaining to class of warrant or rights, exercised during the period. No definition available.
|
| X | ||||||||||
- Definition Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Amount of asset acquired in excess of (less than) liability assumed in business combination and recognized at acquisition date. Excludes goodwill. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Amount of impairment loss from asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|